Barrier packaging is one of the most commercially attractive nanoclay applications, and it is also the one where the regulatory gate is highest. An additive that is unremarkable in an automotive part becomes a regulated food-contact substance the moment it goes into a film that will touch a sandwich.
This article covers the compliance pathway only — what has to be authorized, what has to be demonstrated, and how the approval routes differ. It does not address formulation or performance.
The organizing question: what actually has to be authorized
In food contact, the regulated object is not “the packaging.” It is the substance, in the specific form used, for the specific conditions of use. Change the form and you have, for regulatory purposes, potentially changed the substance.
This is the central fact for nanoclay. The nanoform is not carried along by an authorization granted to the bulk mineral. It has to be authorized in its own right.
European Union: Regulation (EU) No 10/2011
Plastic materials and articles intended for food contact are governed by Commission Regulation (EU) No 10/2011, which sits within the framework of Regulation (EC) No 1935/2004 and alongside the good manufacturing practice requirements of Regulation (EC) No 2023/2006.
The nanoform rule is the first thing to understand. Article 9(2) of the Plastics Regulation states that substances in nanoform may only be used if they are explicitly authorized and mentioned in the specifications in Annex I. This is a positive-list system with no back door: absence from the list is a prohibition, not a gap.
Two consequences follow, and both surprise people:
First, the functional barrier derogation does not help you. Regulation 10/2011 permits certain non-authorized substances to be used behind a functional barrier, subject to conditions. Substances in nanoform are carved out of that derogation. Burying an unauthorized nanoclay in an inner layer does not solve the problem.
Second, an Annex I entry for the conventional substance does not cover the nanoform. If you are relying on an existing authorization, check whether the entry’s specifications actually address the nanoform. If they are silent, assume you are not covered.
The migration limits
Two limits operate in parallel.
Overall Migration Limit (OML). The total of all non-volatile substances migrating from the plastic into food may not exceed 10 mg per dm² of food-contact surface area. For a cubic package containing 1 kg of food — the standard assumption of 6 dm² per kg — this corresponds to 60 mg/kg. The OML is a general test of the material’s inertness, not a substance-specific one.
Materials intended for food for infants and young children are treated differently: the limit is expressed on a mass basis rather than a surface-area basis, precisely because the higher surface-to-volume ratio of small packaging would otherwise permit higher intake per kilogram of body weight.
Specific Migration Limits (SML). Individual substances on the Union list carry their own limits, expressed in mg of substance per kg of food, set by EFSA on the basis of the toxicological data for that substance.
A detail that trips up anyone working from older guidance: the generic SML of 60 mg/kg no longer exists. It applied to substances listed without a specific limit, and it was removed by Commission Regulation (EU) 2016/1416, which deleted Article 11(2). EFSA has since been working through the several hundred substances that were previously covered by it. Do not assume a default limit protects you.
Demonstrating compliance
Testing is not optional and it is not ad hoc.
Compliance with the OML is demonstrated by testing against food simulants under standardized conditions of time and temperature representing the worst foreseeable use, following the EN 1186 standard series. Annex III of the Regulation assigns simulants to food categories; Annex V sets the test conditions. Water, notably, is treated as a food rather than a simulant, and is only used for testing materials intended for contact with water.
Specific migration testing is mandated by Article 11. The whole exercise is meant to reproduce realistic worst-case exposure — long-term storage of all food types at room temperature is a different test from short-term hot fill, and the simulant and conditions change accordingly.
The output is a Declaration of Compliance supported by a documentation file, which downstream users and enforcement authorities are entitled to see. In practice, the DoC and its supporting file are the deliverable. Everything else is upstream of it.
The authorization route if your substance is not listed
If the nanoclay you want to use is not on Annex I in nanoform, the pathway runs through EFSA. A petition is submitted with a data package addressing identity, physicochemical characterization, migration, and toxicology. The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids evaluates it and issues an opinion; the Commission then decides whether to amend Annex I.
Two things to know about this route. It is slow — measured in years, not months. And the nano-specific data expectations are heavier than for conventional substances, because the Panel will want characterization sufficient to establish what is actually migrating, if anything, and in what form.
United States: a different architecture
The US does not operate a single positive list with a nano carve-out. It offers several routes, and the choice among them is a strategic decision.
Food Contact Notification (FCN). The default modern pathway. A notification is submitted to FDA containing identity, intended use, migration data, and a safety assessment. Unless FDA objects within 120 days, the notification becomes effective. The critical feature: an FCN is proprietary to the notifier. It authorizes that company’s substance for that use — a competitor cannot rely on it. This makes the FCN commercially attractive as well as regulatorily necessary.
GRAS. Some clay minerals have long-standing GRAS status for food-contact applications. The same caution as in Europe applies with equal force: GRAS status established for a conventional form of a mineral cannot simply be assumed to extend to an engineered nanoform intended to perform differently. FDA has been explicit across contexts that a change in manufacturing process to the nanoscale can warrant a fresh safety evaluation, and that the existence of a prior determination is not dispositive.
Threshold of Regulation. For substances migrating at extremely low levels, an exemption route exists. The dietary concentration thresholds are low and the route is not available where there is a carcinogenicity concern.
Prior sanctions and existing regulations. Some substances are covered by pre-existing regulations in 21 CFR. As above, check whether the form matters.
FDA’s stated approach to nanomaterials has generally been that “nano” is not a hazard classification in itself, but that a change in particle size can change safety-relevant properties and therefore may require new data. Practically: expect to be asked to justify why existing data covers your form, and expect that answer to be scrutinized.
Where these processes stall
A few failure patterns recur.
Assuming the bulk authorization travels. This is the most common and the most expensive. It surfaces late, usually when a customer’s regulatory function asks for the Declaration of Compliance and the file cannot support it.
Inadequate characterization. Both EFSA and FDA will want to know what the material actually is: particle size distribution by an appropriate method, aggregation and agglomeration state, and composition including impurities. A supplier data sheet is not a characterization dossier.
Ignoring the modifier. For organoclays, the quaternary ammonium modifier is a substance in its own right with its own migration and toxicology profile. It is entirely possible for the clay to be unproblematic and the modifier to be the thing that fails. Assess both.
Treating the functional barrier as an escape. In the EU, for nanoforms, it is not.
Working from stale guidance. The removal of the generic SML in 2016 is a good example of a change that quietly invalidated a lot of institutional knowledge. Verify against current consolidated texts.
The practical sequence
For anyone planning a food-contact nanoclay program, the order of operations matters more than the effort:
- Determine regulatory status before technical development, not after. Whether the nanoform is authorized in your target market is a gating question. Finding out at the end that it is not can strand a substantial development program.
- Get characterization data early, to a standard that would survive a regulatory review rather than a sales conversation.
- Assess the modifier separately from the mineral.
- Identify the pathway and its timeline, and build that timeline into the commercial plan. An EFSA petition is not a formality you slot in before launch.
- Build the compliance file as you go. The Declaration of Compliance is assembled from documents that are much easier to generate contemporaneously than to reconstruct.
The bottom line
Food contact is the most demanding regulatory environment nanoclay routinely encounters, and the reason is a single structural fact: the nanoform is treated as its own substance. Every shortcut people reach for — the bulk authorization, the functional barrier, the GRAS listing, the supplier’s assurance — runs into that fact.
Plan for it at the start of the program and it is a manageable, if slow, process. Discover it at the end and it is a stranded investment.
This article is general information, not legal or regulatory advice. Food-contact requirements depend on your specific substance, form, use conditions, and market, and the rules change. Confirm current requirements with qualified regulatory counsel before placing product on any market.